로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Cell > NF-κB > CHEK-ATF048

NF-κB (Luc) HEK293 Reporter Cell

Order Now

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required
  • Description
    The NF-kB (Luc) HEK293 Reporter Cell was engineered with the NF-kB response element driving luciferase expressing systems. The receptors expressing endogenously or transfected on this reporter cell were activated by corresponding ligands binding, transducing intracellular signals resulting in NF-kB-RE mediated luminescence.
  • Application

    • The discovery of activators or inhibitors by the NF-kB signaling bioactivity

    • Transfection host for some receptors concerning the NF-kB signaling pathway

     NF-κB Assay Principles

  • Growth Properties
    Adherent
  • Selection Marker
    Puromycin (2 μg/mL)
  • Complete Growth Medium
    DMEM medium + 10% FBS
  • Freeze Medium
    Serum-free cell cryopreservation medium
  • Quantity
    1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
  • Storage
    Frozen in liquid nitrogen.
  • Mycoplasma Testing
    Negative
  • Sterility Testing
    Negative
  • Instructions for Use
    See data sheet for detailed culturing and assay protocol.

Signaling Bioassay
 NF-κB SIGNALING

Response to human TNFα protein (RLU).
The NF-kB (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TNFα protein (Cat. No. TNA-H4211). The EC50 was approximately 0.64 ng/mL.

 NF-κB SIGNALING

Response to human TNFα protein (FOLD).
The NF-kB (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TNFα protein (Cat. No. TNA-H4211). The max induction fold was approximately 235.

Passage Stability
 NF-κB PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing NF-kB (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human TNFα protein (Cat. No. TNA-H4211). Human TNFα protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 8-26.

Please contact us if you are interested in related cell pool service.

  • Limited Use&License Disclosure

    BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

    1. If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
    2. Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
    3. This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use . You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
    4. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
    5. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
    6. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $10550.00

Drug Development Status

  • Number of Launched Drugs:11 Details
  • Number of Drugs in Clinical Trials:38 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop